头颈部鳞癌相关生物标志物与免疫治疗预后的关系

doi:10.11904/j.issn.1002-3070.2021.01.011

摘要/Abstract

摘要： 头颈部鳞癌(HNSCC)是世界上第六大常见的恶性肿瘤,每年发病超过55万,死亡超过30万人,吸烟和饮酒是其主要危险因素。HNSCC的治疗方案主要是基于TNM分期、以外科手术为主的综合疗法(放疗、化疗及生物治疗)。对于HNSCC的治疗,其5年生存率近年来一直没有改善,因此,需要新的治疗方法提高患者生存率,改善患者生活质量。当今研究热点是以免疫治疗为主的生物靶向治疗在HNSCC的广泛应用,本研究旨在探讨HNSCC相关生物标志物与免疫治疗预后的关系。

关键词: 头颈部鳞癌, HPV, p16, EBV, 预后, 免疫治疗

Abstract: Head and neck squamous cell carcinoma(HNSCC)is the sixth most common malignant tumor in the world,with an annual incidence of more than 550,000 cases and 300,000 deaths.Smoking and drinking alcohol are the main risk factors.The treatment plan of HNSCC is mainly based on TNM staging and primary surgery with comprehensive therapy(radiotherapy,chemotherapy and biological therapy).For the treatment of HNSCC,the 5-year survival rate has not improved in recent years.Therefore,new treatment methods are needed to increase the survival rate and improve the quality of patient life.The current research hotspot is the widespread application of immunotherapy-based biological targeted therapy for HNSCC.This study aims to explore the relationship between biomarkers of HNSCC and prognosis of immunotherapy.

Key words: Head and neck squamous cell carcinoma(HNSCC), HPV, p16, EBV, Prognosis, Immunotherapy

中图分类号:

R739.81

张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.

ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy[J]. Journal of Practical Oncology, 2021, 35(1): 55-58.

参考文献

1 Castellsagué X,Alemany L,Quer M,et al.HPV involvement in head and neck cancers:comprehensive assessment of biomarkers in 3680 patients[J].J Natl Cancer Inst,2016,108(6):403.
2 Fung N,Faraji F,Kang H,et al.The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma[J].Cancer Metastasis Reviews,2017,36(3):449-461.
3 Ang KK,Harris J,Wheeler R,et al.Human papillomavirus and survival of patients with oropharyngeal cancer[J].N Engl J Med,2010,363(1):24-35.
4 Partlová S,Bouˇc ek J,Kloudová K,et al.Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma[J].Oncoimmunology,2015,4(1):e965570.
5 Wherry EJ,Ha SJ,Kaech SM,et al.Molecular signature of CD8⁺T cell exhaustion during chronic viral infection[J].Immunity,2007,27(4):670-684.
6 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicentre,phase 1b trial[J].Lancet Oncol,2016,17(7):956-965.
7 Seiwert TY,Zuo Z,Keck MK,et al.Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas[J].Clin Cancer Res,2015,21(3):632-641.
8 Nasri E,Wiesen LB,Knapik JA,et al.Eps8 expression is significantly lower in p16+ head and neck squamous cell carcinomas(HNSCCs)compared with p16-HNSCCs[J].Hum Pathol,2018,72:45-51.
9 Ferris RL,Blumenschein G Jr,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].N Engl J Med,2016,375(19):1856-1867.
10 Prigge ES,Arbyn M,von Knebel Doeberitz M,et al.Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas:a systematic review and meta-analysis[J].Int J Cancer,2017,140(5):1186-1198.
11 Cai L,Ye Y,Jiang Q,et al.Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma[J].Nat Commun,2015,6:7353.
12 Kang H,Kiess A,Chung CH.Emerging biomarkers in head and neck cancer in the era of genomics[J].Nat Rev Clin Oncol,2015,12(1):11-26.
13 Chan JY,Wong ST.The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma[J].Laryngoscope,2014,124(1):126-130.
14 Straathof KC,Bollard CM,Popat U,et al.Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes[J].Blood,2005,105(5):1898-1904.
15 Louis CU,Straathof K,Bollard CM,et al.Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma[J].J Immunother,2010,33(9):983-990.
16 Comoli P,Pedrazzoli P,Maccario R,et al.Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes[J].J Clin Oncol,2005,23(35):8942-8949.
17 Li YY,Chung GT,Lui VW,et al.Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations[J].Nat commun,2017,8:14121.
18 张锐,王智煜,文孝婷,等.肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J].实用肿瘤学杂志,2016,30(2):167-171.
19 Cristescu R,Mogg R,Ayers M,et al.Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy[J].Science,2018,362(6411):3593.
20 Solomon B,Young RJ,Rischin D.Head and neck squamous cell carcinoma:genomics and emerging biomarkers for immunomodulatory cancer treatments[J].Semin Cancer Biol,2018,52(2):228-240.
21 Ferris RL.Immunology and immunotherapy of head and neck cancer[J].J Clin Oncol,2015,33(29):3293-3304.
22 Srivastava RM,Lee SC,Andrade Filho PA,et al.Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients[J].Clin Cancer Res,2013,19(7):1858-1872.
23 Ohtani T,Yamada Y,Furuhashi A,et al.Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers[J].Int J Oncol,2014,45(5):2051-2057.
24 李川,李燕,白鹰.细胞因子疗法在肿瘤治疗中的应用[J].国际肿瘤学杂志,2013,40(8):590-592.

[1]	李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.
[2]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[3]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.
[4]	左蕊, 金路, 刘丽, 刘小嘉, 赵鹏宇, 向小燕. miR-409-3p在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 554-559.
[5]	刘恒昌, 魏然, 李春香, 刘正, 陈海鹏, 关旭, 赵志勋, 邹霜梅, 王锡山, 姜争. NOX4在结肠癌组织中的表达及与预后的关系[J]. 实用肿瘤学杂志, 2020, 34(5): 391-397.
[6]	孙小艳, 张晓艳. LncRNA-SChLAP1在结直肠癌组织中高表达的预后评估意义[J]. 实用肿瘤学杂志, 2020, 34(5): 425-429.
[7]	尹松祥. Copine-8在胃癌组织中的表达与临床病理特征及预后的相关性[J]. 实用肿瘤学杂志, 2020, 34(5): 430-435.
[8]	魏勇, 张玉海, 吕双双, 李月敏. 合并重症肌无力对胸腺瘤术后患者预后的影响[J]. 实用肿瘤学杂志, 2020, 34(4): 341-346.
[9]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[10]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[11]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[12]	王棹, 冯越, 邢丽楠, 张云艳. PLR与恶性肿瘤同步放化疗预后的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 271-275.
[13]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[14]	苏文佳, 王树叶. 滤泡性淋巴瘤的预后分层和治疗进展[J]. 实用肿瘤学杂志, 2020, 34(2): 189-192.
[15]	廖代祥, 郑博, 张彦斌, 于军辉. RRBP1与RABEX-5蛋白在结直肠癌组织中的表达及与临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2020, 34(1): 43-48.